CancerLinQ®

CancerLinQ is a health technology company focused on improving cancer care quality and clinical research with real-world data and advanced analytics.

[CancerLinQ® @CancerLinQOrg]

Join us at #RSNA25 in the ConcertAI booth (#6106) as we share our latest innovations, including TeraRecon DETECT, our newly announced AI-powered platform that unifies clinical and operational workflows. Let's meet: https://t.co/bKrUCYRcTF

[CancerLinQ® @CancerLinQOrg]

#RSNA2025 is right around the corner! Be sure to stop by and connect with us at the ConcertAI booth #6106 — we can’t wait to see you there! Schedule a meeting with our team: https://t.co/z4M3IwUEO7

[CancerLinQ® @CancerLinQOrg]

We're excited to connect with healthcare leaders at the ASCO Quality Care Symposium in Chicago, Oct 10-11! Stop by the 4th Floor, Grand Horizon Ballroom for a live demo to see how CancerLinQ can elevate care quality and close treatment gaps!

Schedule a time to chat with our team: https://t.co/lkGHeHd15e

[CancerLinQ® @CancerLinQOrg]

We're excited to share that CancerLinQ®, an initiative of ConcertAI, is now an American Society of Clinical Oncology (ASCO) Certified Recognized Quality Solution (RQS)! This achievement means oncology practices can now automate quality tracking, saving crucial time and resources to focus on patient care. Our dedication to data integrity and improving patient outcomes is at the heart of this milestone.

Learn more about how we're advancing oncology care: https://t.co/WfJhPWwkAy

[CancerLinQ® @CancerLinQOrg]

World Lung Cancer Day has been observed annually on August 1 to raise awareness about lung cancer and emphasize the critical need for increased research funding. Today, we stand together to support those affected by this challenging disease, honor the resilience of survivors, and push for continued advancements in treatment.

Our CancerLinQ team at @ConcertAI is dedicated to advancing lung cancer research, with over 30 publications on the topic. We remain committed to fostering progress and advancements in lung cancer treatment.

Check out our publications: https://t.co/tgQVyBakK6

#WorldLungCancerDay, #LungCancerAwareness, #WLCD25 #LungCancerAwareness #CancerResearch

[CancerLinQ® @CancerLinQOrg]

We're looking for dedicated and innovative individuals to join our CancerLinQ team. As part of the team, you'll contribute to meaningful projects that enhance patient outcomes and improve the quality of care. Explore opportunities here: https://t.co/tbQnzhxy8n #JoinConcertAI

[CancerLinQ® @CancerLinQOrg]

Didn't catch our latest webinar live? Unlock the Insights On Demand! 🎥

Discover how real-world data analysis is revolutionizing prostate cancer research. Watch our latest webinar featuring Dr. Corbin Eule from the University of Colorado Anschutz Medical Campus, as he unveils groundbreaking findings from his recent research.

Watch now: https://t.co/sWuIrhL2cY

#Webinar #CancerResearch #ProstateCancer #RealWorldData #CancerLinQ #MedicalOncology

[CancerLinQ® @CancerLinQOrg]

Discover how real-world data analysis is accelerating breakthroughs and deepening our comprehension of prostate cancer. Join us TOMORROW at 12:00 PM ET for our CancerLinQ #webinar series! We're thrilled to have Dr. Corbin Eule from the University of Colorado Anschutz Medical Campus sharing his groundbreaking insights using CancerLinQ datasets.

Register Now: https://t.co/Ytnuj0Owy8

[CancerLinQ® @CancerLinQOrg]

New Upcoming Webinar! 🌟

Join us on July 15 at 12:00 PM ET for our Webinar: "Accelerating Discovery: Uncovering Real-World Patterns Using CancerLinQ Data." We're excited to feature Dr. Corbin Eule, Assistant Professor of Genitourinary Medical Oncology at the University of Colorado Anschutz Medical Campus, who will share groundbreaking insights from his recent prostate cancer research using CancerLinQ datasets.

Discover how analyzing real-world data patterns can accelerate discovery and deepen our understanding of prostate cancer. These datasets are crucial for data-driven research, especially when resources are limited. Don't miss this opportunity to learn from a leading expert in the field!

Register now to secure your spot: https://t.co/nuHcvlUE3Z

#Webinar #CancerResearch #ProstateCancer #RealWorldData #CancerLinQ #MedicalOncology

[CancerLinQ® @CancerLinQOrg]

We had an amazing time at the ASCO Annual Meeting! A huge thank you to everyone who visited our team! Your engaging conversations were truly inspiring, and we're excited to keep them going!

At the event, ConcertAI proudly announced the integration of American Society of Clinical Oncology (ASCO) Guidelines into our CancerLinQ® SmartLinQ™ solutions. This means that members of the CancerLinQ® network using SmartLinQ will now benefit from ASCO Guideline-concordant recommendations, enhancing their assessment of treatment options with personalized insights for individual patients.

Missed us at the ASCO Annual Meeting? No problem! We're eager to demonstrate how you can streamline QOPI/ASCO Certification, elevate the quality of care, pinpoint novel targeted therapies for patients, and gain valuable insights into cancer patient populations. Schedule a demo today: https://t.co/jcNUqXFmTZ #ASCO25

[CancerLinQ® @CancerLinQOrg]

Although triple-negative breast cancer (TNBC) is known to be an aggressive subtype, less is understood about the possible role of adjuvant chemotherapy for small T1 tumors < 1 cm. In this retrospective analysis using the real-world database CancerLinQ Discovery®, Dr. Kai Johnson and co-investigators from @OhioState analyzed recurrence and survival data for a cohort of patients with T1mi/a/b N0 TNBC tumors following curative surgery. Among 159 patients, 48% received adjuvant taxane-cyclophosphamide (TC), 25% received an anthracycline + cyclophosphamide followed by a taxane (AC-T), and the rest did not receive adjuvant systemic therapy. After a median follow-up of nearly 5 years, there was a statistically significant benefit in terms of invasive recurrence-free survival and overall survival for patients receiving either TC or AC-T compared with locoregional therapy alone. The authors conclude that there is benefit to adjuvant chemotherapy even in this clinically low-risk population. This study, which used real-world data aggregated from across the CancerLinQ network, provides valuable insights into the optimal management of TNBC, especially for this less commonly encountered subset.

Join us for the poster session at the ASCO Annual Meeting tomorrow, June 2nd, from 9:00 AM to 12:00 PM to learn more. Read the abstract here: https://t.co/7iI5YSTj3T.

[CancerLinQ® @CancerLinQOrg]

The 2025 ASCO Annual Meeting is in full swing, and our team is having a fantastic time!

Swing by the ConcertAI booth #14046 to discover how SmartLinQ is empowering oncology teams with actionable insights. Identify care gaps, support trial screening, and enhance clinical decision-making with data from 9.5 million patients. Don't miss out on this opportunity to revolutionize your approach to oncology care!

#ASCO2025 #OncologyInnovation #SmartLinQ

[CancerLinQ® @CancerLinQOrg]

Big news out of Chicago today! At the ASCO Annual Meeting, ConcertAI is excited to announce that we're integrating ASCO Guidelines into CancerLinQ® SmartLinQ™ solutions.

Read the announcement: https://t.co/ZlAtPzcOQv

Attending the ASCO Annual Meeting? Visit us in booth 14046 to learn more!

#ASCO2025 #CancerLinQ #OncologyInnovation

[CancerLinQ® @CancerLinQOrg]

Studying the side effect profiles of targeted therapies remains challenging due to the passive collection of existing post-marketing surveillance databases and the infrequent use of specific medications within single cancer centers. Using the CancerLinQ Discovery database, which collects deidentified longitudinal EHR data from millions of patients around the US, Dr. Joseph Vento and co-investigators applied algorithms using high-throughput association studies to side effect diagnosis codes of patients with non-small cell lung cancer receiving targeted therapies, for active side effect characterization. This workflow not only detected known side effects of specific agents but also potentially underreported toxicities. Using data from large, aggregated databases like CancerLinQ can overcome some of the limitations affecting single-institution analyses and provide more comprehensive and potentially actionable insights.

Join this exciting poster session at the ASCO Annual meeting on Sunday, June 1 from 9:00 AM - 12:00 PM.

Read the abstract: https://t.co/MRZ6lX3uOG

[CancerLinQ® @CancerLinQOrg]

Can you believe the ASCO Annual Meeting starts tomorrow? Join us at the @ConcertAI booth #14046 to meet with our team. We can’t wait to connect with you!

Carole Termoni, Senior Director Provider Partnerships & Customer Success shares her anticipation:
“CancerLinQ and ConcertAI are harnessing the power of AI to transform the cancer patient journey. By uncovering insights around diagnosis, treatment, social determinants of health, and outcomes, we're committed to enhancing cancer care and advancing the science of oncology.”

[CancerLinQ® @CancerLinQOrg]

The 2025 ASCO Annual Meeting is just a week away, and we can't wait to connect with everyone! Join us at the @ConcertAI booth #14046 to see our latest innovations.

Dr. Robert Miller shares his excitement:
“The theme of the 2025 ASCO Annual Meeting, ‘Driving Knowledge to Action: Building a Better Future,’ perfectly aligns with our vision at CancerLinQ: to learn from every patient to reach every patient, ensuring that all benefit from precision oncology. With the latest advances in generative AI, we're offering comprehensive solutions to cancer centers and oncology practices to enhance cancer care quality and advance discovery. Visit the ConcertAI booth #14046 in the Exhibit Hall to see how the SmartLinQ platform delivers advanced tools for quality measurement, practice intelligence, clinical decision support, and research facilitation.”

Schedule a meeting with us: https://t.co/alGrJYfWRc

#ASCO2025 #CancerLinQ #OncologyInnovation

[CancerLinQ® @CancerLinQOrg]

Missed the live webinar? No problem! Catch up on our on-demand session about bridging gaps in oncology care. Gain insights from experts Mohana Roy, MD and Arpan Patel, MD, MBA. Watch now: https://t.co/GCvTvIpJqh!

[CancerLinQ® @CancerLinQOrg]

Can you believe the 2025 ASCO Annual Meeting is just a couple of weeks away? Join us at the ConcertAI booth #14046 to discover how CancerLinQ can streamline QOPI/ASCO Certification, enhance quality of care, identify novel targeted therapies for patients, and uncover insights about cancer patient populations. Schedule a meeting with our team: https://t.co/xaHgH2RGQZ

#ASCO2025 #CancerLinQ #OncologyInnovation

[CancerLinQ® @CancerLinQOrg]

Reflecting on our incredible experience at the ONCare Spring 2025 National Leadership Summit in San Diego last week! A heartfelt thank you to the ONCare Alliance and Exigent Research Network for hosting such an impactful event.

At CancerLinQ, we cherish our strong relationships with many ONCare sites, which naturally complement and align with ConcertAI’s goals. It was fantastic reconnecting with familiar faces and showcasing how ConcertAI’s Digital Trial Solutions are advancing clinical research.

We were honored to present our trial screening solutions and host two dynamic workshop sessions, where physicians brought their own topics and questions. The lively and insightful discussions sparked great interest in what’s possible through our collaborative support.

Excited for more great discussions ahead!

[CancerLinQ® @CancerLinQOrg]

There is still time to register! 🚨

Join us tomorrow at 12:00 PM ET for an insightful webinar focused on bridging the gaps in oncology care from diagnosis to outcomes. Gain exclusive insights from two esteemed physicians at NCI-designated cancer centers. Don't miss this opportunity to learn how to enhance patient outcomes in your practice!

Secure your spot: https://t.co/awMTsDg8WD